September 21, 2021
RFA-DA-22-022 - Fentanyl and its Analogs: Effects and Consequences for Treatment of Addiction and Overdose (UG3/UH3, Clinical Trial Optional)
National Institute on Drug Abuse (NIDA)
This notice clarifies the "Award Budget" in Section II. Award Information of RFA-DA-22-022. UG3 application budgets are limited to $500k in direct costs per year. UH3 phase application budgets should not exceed $1 million in direct costs per year. Application budgets should reflect the actual needs of the project.
Aidan Hampson, Ph.D.
National Institute on Drug Abuse